The continuing progress and challenges of clinical islet transplantation

Current Opinion in Endocrinology and Diabetes

Volumn 12, Issue 4, 2005, Pages 291-297

  Wiseman, Alexander C ^a   Gill, Ronald G ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Diabetes; Immunity; Islet transplantation

Indexed keywords

GRAFT FAILURE; HUMAN; IMMUNE INJURY; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET TRANSPLANTATION; POSTOPERATIVE COMPLICATION; REVIEW; TREATMENT OUTCOME;

EID: 24044479715     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Hering BJ, Ricordi C. Results, research priorities and reasons for optimism: islet transplantation for patients with type 1 diabetes. Graft 1999; 2:12-27.
2. Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type I diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230-238.
3. Ryan EA, Lakey JRT, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton Protocol. Diabetes 2001; 50:710-719.
4. Ryan EA, Lakey JRT, Paty BW, et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51:2148-2157.
5. McDonald CG, Ryan EA, Paty BW, et al. Cross-sectional and prospective association between proinsulin secretion and graft function after clinical islet transplantation. Transplantation 2004; 78:934-937.
6. Goss JA, Schock AP, Brunicardi FC, et al. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation 2002; 74:1761-1766.
7. Markmann JF, Deng S, Desai NM, et al. The use of non-heart-beating donors for isolated pancreatic islet transplantation. Transplantation 2003; 75:1423-1429.
8. Shapiro AM, Ricordi C, Hering BJ. Edmonton's islet success has indeed been replicated elsewhere. Lancet 2003; 386:1242.
9. Hirshberg B, Rother KI, Digon BJI, et al. Benefits and risks of solitary islet transplanation for Type 1 Diabetes using steroid-sparing immunosuppression. Diabetes Care 2003; 26:3288-3295.
10. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in Type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004; 4:390-401. An important clinical trial that demonstrates insulin independence and putative regulatory T-cell generation using single-donor islet infusions and anti-CD3 depleting antibody.
11. Frank A, Deng S, Huang X, et al. Transplantation for type 1 diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann Surg 2004; 240:631-643.
12. Rickels MR, Schutta MH, Markmann JF, et al. β-Cell function following human islet transplantation for Type 1 diabetes. Diabetes 2005; 54:100-106. This study demonstrates the marginal quality of transplanted islets despite initial insulin independence, both in terms of durable graft function and in terms of impaired insulin secretion when subjected to provocative stimuli.
13. Fiorina P, Folli F, Zerbini G, et al. Islet transplantation is associated with improvement of renal function among uremic patients with Type 1 diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003; 14:2150-2158.
14. Close N, Anand R, Hering B, Eggerman T. NIH-supported national islet transplantation registry. Cell Biochem Biophys 2004; 40(3 Suppl):9-18.
15. Matsumoto I, Sawada T, Nakano M, et al. Improvement in islet yield from obese donors for human islet transplants. Transplantation 2004; 78:880-885.
16. Along with Deng et al. (Diabetes 2004; 53:624-632), highlights the significant dichotomy (yield vs function) in organ selection for islet transplantation and the need to screen organ donors for undiagnosed type 2 diabetes.
17. Deng S, Vatamaniuk M, Huang X, et al. Structural and functional abnormalities in the islets isolated from Type 2 diabetic subjects. Diabetes 2004; 53:624-632.
18. Along with Matsumoto et al. (Transplantation 2004; 78:880-885), highlights the significant dichotomy (yield vs function) in organ selection for islet transplantation and the need to screen organ donors for undiagnosed type 2 diabetes.
19. Lakey JR, Kneteman NM, Rajotte RV, et al. Effect of core pancreas temperature during cadaveric procurement on human islet isolation and functional viability. Transplantation 2002; 73:1106-1110.
20. Lee TC, Barshes NR, Brunicardi FC, et al. Procurement of the human pancreas for pancreatic islet transplantation. Transplantation 2004; 78:481-483.
21. Sawada T, Matsumoto I, Nakano M, et al. Improved islet yield and function with ductal injection of University of Wisconsin solution before pancreas preservation. Transplantation 2003; 75:1965-1969.
22. Tsujimura T, Kuroda Y, Avila JG, et al. Influence of pancreas preservation on human islet isolation outcomes: impact of the two-layer method. Transplantation 2004; 78:96-100.
23. Tsujimura T, Kuroda Y, Churchill TA, et al. Short-term storage of the ischemically damaged human pancreas by the two-layer method prior to islet isolation. Cell Transplant 2004; 13:67-73.
24. Brandhorst H, Brandhorst D, Hesse F, et al. Successful human islet isolation utilizing recombinant collagenase. Diabetes 2003; 52:1143-1146.
25. Bucher P, Mathe Z, Morel P, et al. Assessment of a novel two-component enzyme preparation for human islet isolation and transplantation. Transplantation 2005; 79:91-97. This article presents an important advance in islet isolation, the development of a collagenase blend that may minimize lot-to-lot variablity and permit titration of enzyme concentration for specific donor and pancreas characteristics.
26. Goto M, Eich TM, Felldin M, et al. Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture. Transplantation 2004; 78:1367-1375.
27. Ricordi C. Lilly lecture 2002. Islet transplantation: a brave new world. Diabetes 2003; 52:199-203.
28. Fraker C, Montelongo J, Szust J, et al. The use of multiparametric monitoring during islet cell isolation and culture: a potential tool for in-process corrections of critical physiological factors. Cell Transplant 2004; 13:497-502.
29. Ichii H, Pileggi A, Molano RD, et al. Rescue purification maximizes the use of human islet preparations for transplantation. Am J Transplant 2005; 5:21-30. An important contribution to present-day islet isolation, this technique permits low-yield but otherwise acceptable islet preparations to reach quantities sufficient for transplant.
30. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293:830-835. The most successful single-donor islet transplant success published to date, this study describes a number of features that may improve the odds for successful transplantation, including donor selection, anticoagulation, and immunosuppression.
31. Pinske GGM, Steenvoorde E, Hogenoorn S, et al. Stable transplantation results of magnetically retracted islets: a novel method. Diabetologia 2004; 47:55-61. A provocative technical report that, if applicable to human pancreatic tissue, could lead to greater yields with less islet injury.
32. Markmann JF, Deng S, Huang X, et al. Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg 2003; 237:741-750.
33. Barshes NR, Lee TC, Brunicardi FC, et al. Lack of cytomegalovirus transmission after pancreatic islet transplantation. Cell Transplant 2004; 13:833-838.
34. Hafiz MM, Poggioli R, Caulfield A, et al. Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with Type 1 diabetes mellitus. Am J Transplant 2004; 4:1697-1702.
35. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 2004; 279: 42351-42354. A proposed mechanism describing factors that lead to early islet graft failure in the absence of alloimmune or autoimmune injury. Important as it may form the basis for therapies directed at chronic targeted suppression of oxidant stress in islet grafts with marginal function.
36. Man D, Xu X, Baidal D, et al. Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes 2004; 53:2281-2290. An important first step in the search for a tool that can monitor for acute rejection in islet transplants.
37. Paty BW, Bonner-Weir S, Laughlin MR, et al. Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health workshop on beta cell imaging. Transplantation 2004; 77:1 133-1137. A good introduction to the current challenges of quantifying and characterizing islets in preparation for transplantation.
38. Brennan DC, Shannon MB, Koch MJ, et al. Portal vein thrombosis complicating islet transplantation in a recipient with the factor V Leiden mutation. Transplantation 2004; 78:172-173.
39. Barshes NR, Lee TC, Goodpastor SE, et al. Transaminitis after pancreatic islet transplantation. J Am Coll Surg 2005; 200:353-361.
40. Bhargava R, Senior PA, Ackerman TE, et al. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 2004; 53:1311-1317.
41. Markmann JF, Rosen M, Siegelman ES, et al. Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes 2003; 52:1591-1594.
42. Thomas D, Yang H, Boffa DJ, et al. Proapoptotic bax is hyperexpressed in isolated human islets compared with antiapoptotic bcl-2. Transplantation 2002; 74:1489-1496.
43. Giuliani M, Moritz W, Bodmer E, et al. Central necrosis in isolated hypoxic human pancreatic islets: evidence for postisolation ischemia. Cell Transplant 2005; 14:67-76.
44. Bottino R, Balamurugan AN, Tse H, et al. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes 2004; 53: 2559-2568.
45. Nakano M, Matsumoto I, Sawada T, et al. Caspase-3 inhibitor prevents apoptosis of human islets immediately after isolation and improves islet graft function. Pancreas 2004; 29:104-109.
46. Biarnes M, Montolio M, Nacher V, et al. β-Cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 2002; 51:66-72.
47. Bottino R, Balamurugan AN, Bertera S, et al. Preservation of human islet cell functional mass by anti-oxidative action of a novel SOD mimic compound. Diabetes 2002; 51:2561-2567.
48. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol 2005; 77:587-597. [Epub 2005 Feb 22.]
49. Abdelli S, Ansite J, Roduit R, et al. Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposure. Diabetes 2004; 53:2815-2823.
50. Viswanathan K, Dhabhar FS. Stress-induced enhancement of leukocyte trafficking into sites of surgery or immune activation. Proc Natl Acad Sci USA 2005; 102:5808-5813. An elegant study that highlights the importance of innate immunity, this report has direct implications to the injury pattern sustained by islets in the peritransplant period.
51. Bennet W, Sundberg B, Groth CG, et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 1999; 48:1907-1914.
52. Beuneu C, Vosters O, Movahedi B, et al. Human pancreatic duct cells exert tissue factor-dependent procoagulant activity: relevance to transplantation. Diabetes 2004; 53:1407-1411.
53. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360:2039-2045.
54. Moberg L, Olsson A, Berne C, et al. Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation 2003; 76:1285-1288.
55. Bertuzzi F, Marzorati S, Maffi P, et al. Tissue factor and CCL2/monocyte chemoattractant protein-1 released by human islets affect islet engraftment in type 1 diabetic recipients. J Clin Endocrinol Metab 2004; 89:5724-5728.
56. Movahedi B, Van de Casteele M, Caluwe N, et al. Human pancreatic duct cells can produce tumour necrosis factor-a that damages neighbouring beta cells and activates dendritic cells. Diabetologia 2004; 47:998-1008. This study provides evidence that ductal cells in impure islet fractions may contribute significantly to islet loss.
57. Vosters O, Beuneu C, Nagy N, et al. CD40 expression of human pancreatic duct cells: role in nuclear factor-kappa B activation and production of proinflammatory cytokines. Diabetologia 2004; 47:660-668.
58. Desai NM, Goss JA, Deng S, et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxcity? Transplantation 2003; 76:1623-1637.
59. Shapiro AMJ, Gallant H, Hao EG, et al. The portal immunosuppressive storm: relevance to islet transplantation. Ther Drug Monit 2005; 27:35-37.
60. Mattsson G, Jansson L, Nordin A, et al. Evidence of functional impairment of syngeneically transplanted mouse pancreatic islets retrieved from the liver. Diabetes 2004; 53:948-954.
61. Laybutt DR, Sharma A, Sgroi DC, et al. Genetic regulation of metabolic pathways in β-cells disrupted by hyperglycemia. J Biol Chem 2002; 277:10912-10921.
62. Maedler K, Sergeev P, Ris F, et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110:851-860.
63. Robertson RP, Lanz KJ, Sutherland DER, Kendall DM. Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. Diabetes 2001; 50:47-50.
64. Brendel MD, Hering BJ, Schultz AO, Bretzel RG. ITR newsletter #9. International Islet Transplant Registry 2001; 8:1-20.
65. Farney AC, Hering BJ, Nelson L, et al. No late failures of intraportal human islet autografts beyond 2 years. Transplant Proc 1998; 30:420.
66. Tran POT, Parker SM, LeRoy E, et al. Adenoviral overexpression of the glutamylcysteine ligase catalytic subunit protects pancreatic islets against oxidative stress. J Biol Chem 2004; 52:53988-53993.
67. Avila JG, Tsujimura T, Oberholzer J, et al. Improvement of pancreatic islet isolation outcomes using glutamine perfusion during isolation procedure. Cell Transplant 2003; 12:877-881.
68. Klein D, Ribeiro MM, Mendoza V, et al. Delivery of Bcl-CL or its BH4 domain by protein transduction inhibits apoptosis in human islets. Biochem Biophys Res Commun 2004; 323:473-478. This article is the first the demonstrate that antiapoptotic factors can be transfected to human islets without the use of viral vectors and exhibit a protective phenotype, findings that may hold promise in future clinical trials.
69. Fenjves ES, Ochoa MS, Gay-Rabinstein C, et al. Retrovirally transferred genes inhibit apoptosis in an insulin-secreting cell line: implications for islet transplantation. Cell Transplant 2004; 13:489-496.
70. Contreras JL, Eckstein C, Smyth CA, et al. Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes 2004; 53:2804-2814.
71. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003; 52:2731-2739.
72. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-1698.
73. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belateacept), a high-affinity variant of CTLA4-lg with potent immunosuppressive properties. Am J Transplant 2005; 5:448-453.
74. Along with Adams et al. (J Immunol 2005; 174:542-550), describes further progress in targeting costimulatory pathways in the prevention of rejection and, ideally, the promotion of immunologic tolerance. These therapies may form the basis of future clinical trials in an attempt to avoid current immunosuppression toxicities.
75. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174:542-550.
76. Along with Larsen et al. (Am J Transplant 2005; 5:448-453), describes further progress in targeting costimulatory pathways in the prevention of rejection and, ideally, the promotion of immunologic tolerance. These therapies may form the basis of future clinical trials in an attempt to avoid current immunosuppression toxicities.
77. Nicolls MR, Coulombe M, Beilke J, et al. CD4-dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways. J Immunol 2002; 169:4831-4839.
78. Berney T, Pileggi A, Molano RD, et al. The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. Transplantation 2003; 76:1669-1674.
79. Molano RD, Pileggi A, Berney T, et al. Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154. Diabetes 2003; 52:957-964.
80. Nanji SA, Hancock WW, Anderson CC, et al. Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant 2004; 4:526-536.
81. Zheng XX, Sanchez-Fueyo A, Sho M, et al. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003; 19:503-514.
82. Wijkstrom M, Kenyon NS, Kirchhof N, et al. Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation 2004; 77:827-835.
83. Yang Z, Chen M, Ellett JD, et al. The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation. Transplantation 2004; 77:55-60.
84. Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in islet transplantation. Am J Transplant 2004; 4:295-298.
85. Fiorina P, Folli F, Bertuzzi F, et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in Type 1 diabetic kidney-transplanted patients. Diabetes Care 2003; 26:1129-1136.
86. Fiorina P, Folli F, Maffi P, et al. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 2003; 75:1296-1301.
87. Langer RM, Mathe Z, Doros A, et al. Successful islet after kidney transplantations in a distance over 1000 kilometers: preliminary results of the Budapest-Geneva collaboration. Transplant Proc 2004; 36:3113-3115.